Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Letrozole
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms PRECIOUS
Sponsors Pfizer

21 Feb 2023 Planned End Date changed from 30 Oct 2024 to 30 Apr 2025.
15 Aug 2022 Planned End Date changed from 31 Jul 2024 to 30 Oct 2024.
15 Aug 2022 Planned primary completion date changed from 15 Jun 2021 to 30 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com